Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ Stocks

Company Overview - ProQR is a clinical-stage biotech company focused on developing RNA-based therapies for genetic diseases, utilizing its proprietary Axiomer RNA editing platform to make precise changes at the RNA level [3][12] - The company's lead program, AX-0810, targets NTCP, a liver transport protein, aiming to lower bile acid levels to address cholestatic liver diseases such as primary sclerosing cholangitis and biliary atresia [1][12] Pipeline and Development - ProQR is advancing AX-0810 through a Phase 1 dosing trial, with target engagement data expected in the first half of 2026 [7] - Initial updates on AX-0810 have shown no safety signals after four weeks of dosing, aligning with preclinical expectations [8] - Beyond AX-0810, ProQR is developing AX-2402 for Rett syndrome and AX-2911 for metabolic dysfunction-associated steatohepatitis, with plans to advance AX-2402 into human studies by the first half of 2027 [9] Strategic Collaborations - ProQR has a strategic collaboration with Eli Lilly, focusing on RNA editing therapies for genetically defined targets, which generated $4.5 million in milestone payments in 2025 [10] Market Potential and Analyst Outlook - Analysts, including Oppenheimer's Kostas Biliouris, view ProQR's current share price of $1.37 as an attractive entry point, with a potential upside of 50-100% based on upcoming data [11][12] - The consensus rating for ProQR is a 'Strong Buy', with an average price target of $8.20, indicating a potential surge of approximately 500% over the next year [13] Financial Performance - ProQR's valuation currently assigns minimal credit to AX-0810, which could represent a multi-billion dollar commercial opportunity if successful [12]